Cargando…

The reduction in CD8(+)PD-1(+) T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients

BACKGROUND: Antiviral therapy is recommended for patients with immune-active chronic hepatitis B (CHB) to decrease the risk of liver-related complications. However, the outcomes of the pegylated IFN-α (PEG-IFN-α) therapy vary among CHB patients. We aimed to identify factors that can influence the ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ruyu, Chen, Yanhui, Guo, Jiang, Li, Minghui, Lu, Yao, Zhang, Lu, Shen, Ge, Wu, Shuling, Chang, Min, Hu, Leiping, Hao, Hongxiao, Zhang, Henghui, Xie, Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418392/ https://www.ncbi.nlm.nih.gov/pubmed/32778058 http://dx.doi.org/10.1186/s12879-020-05320-z

Ejemplares similares

The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy
por: Cao, Weihua, et al.
Publicado: (2021)

Dynamic changes of the proportion of HLA-DR and CD38 coexpression subsets on T lymphocytes during IFN-based chronic hepatitis B treatment
por: Lin, Yanjie, et al.
Publicado: (2023)

Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy
por: Cao, Weihua, et al.
Publicado: (2022)

Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment
por: Cao, Weihua, et al.
Publicado: (2022)

Cytokine profiles and CD8+ T cells in the occurrence of acute and chronic hepatitis B
por: Xie, Si, et al.
Publicado: (2022)

Hepatitis B core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic HBV infection after short-course antiviral therapy
por: Liu, Ruyu, et al.
Publicado: (2023)

Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection
por: Wu, Shuling, et al.
Publicado: (2022)

Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy
por: Bi, Xiaoyue, et al.
Publicado: (2023)

Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection
por: Zhang, Lu, et al.
Publicado: (2023)

A nomogram based on HBeAg, AST, and age to predict non-minimal liver inflammation in CHB patients with ALT <80 U/L
por: Zhang, Lu, et al.
Publicado: (2023)

Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
por: Zeng, Zhan, et al.
Publicado: (2023)

Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection
por: Sun, Fangfang, et al.
Publicado: (2022)

Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity
por: Lu, Huihui, et al.
Publicado: (2023)

The relation of the frequency and functional molecules expression on plasmacytoid dendritic cells to postpartum hepatitis in women with HBeAg-positive chronic hepatitis B virus infection
por: Wang, Fuchuan, et al.
Publicado: (2022)

Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
por: Li, Minghui, et al.
Publicado: (2022)

Study on liver histopathology of chronic HBV infected patients with different normal ALT values
por: Zeng, Zhan, et al.
Publicado: (2022)

Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
por: Sherstoboev, E. Yu., et al.
Publicado: (2022)

Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients
por: Li, Minghui, et al.
Publicado: (2022)

Antiproliferative effects of sorafenib and pegylated IFN-α2b on human liver cancer cells in vitro and in vivo
por: KUSANO, HIRONORI, et al.
Publicado: (2013)

IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell
por: Sun, Yao, et al.
Publicado: (2019)

Use of Protein Pegylation to Prolong the Antiviral Effect of IFN Against FMDV
por: Diaz-San Segundo, Fayna, et al.
Publicado: (2021)

Pegylated IFN-α sensitizes melanoma cells to chemotherapy and causes premature senescence in endothelial cells by IRF-1-mediated signaling
por: Upreti, M, et al.
Publicado: (2010)

Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection
por: Aspord, Caroline, et al.
Publicado: (2016)

An Effective Synthesis Method for Tilorone Dihydrochloride with Obvious IFN-α Inducing Activity
por: Zhang, Junren, et al.
Publicado: (2015)

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer
por: Ding, Guoping, et al.
Publicado: (2019)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
por: He, Gaixia, et al.
Publicado: (2015)

CD137 ligand feedback upregulates PD‐L1 expression on lung cancer via T cell production of IFN‐γ
por: Wang, Helin, et al.
Publicado: (2019)

IFNα and IFNγ Impede Marek’s Disease Progression
por: Bertzbach, Luca D., et al.
Publicado: (2019)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response
por: Liu, LanLan, et al.
Publicado: (2020)

Increased Bone Marrow (BM) Plasma Level of Soluble CD30 and Correlations with BM Plasma Level of Interferon (IFN)-γ, CD4/CD8 T-Cell Ratio and Disease Severity in Aplastic Anemia
por: Wu, Qingqing, et al.
Publicado: (2014)

The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
por: Chen, Yanhui, et al.
Publicado: (2020)

Dysregulation of IFN System Can Lead to Poor Response to Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis C
por: Onomoto, Koji, et al.
Publicado: (2011)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Characteristics of oligodeoxyribonucleotides that induce interferon (IFN)-α in the pig and the phenotype of the IFN-α producing cells
por: Domeika, Kristina, et al.
Publicado: (2004)

Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth
por: Lasfar, Ahmed, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t6melhf65itil4p3h1hm5dogpg